|drug1480||Home sample collection of concerning mole with physician supervision Wiki||1.00|
|drug154||Active control:Healthy Living Wiki||1.00|
There is one clinical trial.
The purpose of this study is to reduce melanoma mortality by improving early detection of melanoma with skin self-examination (SSE) among people who self-identify as being at risk and seek care for a concerning mole. Because women are more likely than men to perform SSE, women who are engaged in health promotion by having a recent screening mammogram are the focus of this research. Self-management of melanoma detection with SSE depends on ready access to dermatologists when a concerning mole is detected. In March 2020, the Illinois stay at home order (COVID-19) prohibited non-essential health care, including screening mammography and dermatology office-based care, and both are expected to remain limited until fall 2020. This submission explores a) the effectiveness of targeted melanoma detection (TMD) among women, who identify their risk of having a melanoma, learn to perform SSE, and perform SSE, and b) the effectiveness of adhesive patch-based home sample collection for genomic analysis to rule out melanoma in moles identified by women as concerning.
Description: Self-reported performance of SSE, a custom scale with the frequency and extent of SSE is completed in an online monthly surveyMeasure: Change in SSE performance Time: 90 days
Description: Self-reported identification of concerning mole identified by user assigning scores to the border,color and diameter of the mole. A validated scoring system is used to categorize the border, color and diameter as 1 if normal, 2 if not sure, and 3 if abnormal.The sum of the scores indicates if the mole is concerning (sum of 3= benign, stop checking the mole; sum of 4- 7 monitor the mole for change in the next month; sum of 8-9 = concerning mole make an appointment to see a physician.Measure: Identification of concerning mole Time: 90 days
Description: The quantity of cells obtained for genomic analysis will be assessed. The results of the genomic analysis will be validated with the pathological findings of the biopsied concerning mole. A Student t test will be performed for the null hypothesis of no difference between the genomic analysis and the pathological finding of melanoma.Measure: Effectiveness of adhesive patch-based home sample collection for genomic analysis of concerning moles to rule-out melanoma Time: 90 Days
Description: Self-reported responses to 7 items, each with a 5-point Likert scale (range 7-35) higher score= more anxietyMeasure: Change in skin self-examination anxiety Time: 90 days
Description: Self-reported responses to 7 items, each with a 5-point Likert scale (range 7-35) higher score = greater confidence.Measure: Change in confidence performing mole checks Time: 90 days
Description: Electronic medical record reviewMeasure: Number of physician visits for concerning moles Time: 5 months
Description: Electronic medical record reviewMeasure: Number of biopsies of concerning moles Time: 5 months
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports